Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

WHO issues alert on fake copies of Novo Nordisk's diabetes drug Ozempic

WHO issues alert on fake copies of Novo Nordisk's diabetes drug Ozempic
The MHRA confirmed that Ozempic has been found at two UK wholesalers. Credit: Reuters

Falsified batches of Ozempic (semaglutide) were detected in Brazil, the UK, Northern Ireland and the United States

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries.


This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain.

Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company.

Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines.

Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

WHO has cautioned that falsified medicines could pose health risks, and potentially cause complications resulting from unmanaged blood glucose levels or weight if they lack the necessary raw components.

The agency recommended that patients using these products should buy medicines with prescriptions from licensed physicians and avoid buying from unfamiliar or unverified sources, including online platforms.

Semaglutides belong to a class of medicines called glucagon-like peptide-1 receptor agonists, indicated for treating hyperglycemia (high blood sugar) in people with type 2 diabetes. They are also known to suppress appetite and therefore are being increasingly prescribed for weight loss in some countries. However, Semaglutides are not part of WHO-recommended treatments for diabetes management due to their current high cost.

The agency stated that it is currently working on a rapid advice guideline on the potential use of GLP-1 RAs, including semaglutides, for treating obesity in adults as part of a more comprehensive model of care.

WHO Global Surveillance and Monitoring System (GSMS) has been observing increased reports on falsified semaglutide products across all geographical regions since 2022. Thursday’s alert marks the first official notice issued by the agency following confirmation of some of these reports.

 

More For You

Air pollution in UK linked to thousands of deaths and chronic health conditions

A report by the Royal College of Physicians claims that air pollution was causing harm to almost every organ of the body.

iStock

Royal College of Physicians paints grim picture of air pollution in UK

Doctors warn that around 99 per cent of the population in the UK are breathing "toxic air", and around 30,000 deaths will be linked to air pollution in 2025.

The Royal College of Physicians (RCP) claimed in a report that air pollution was causing harm to almost every organ of the body, and shortening life by 1.8 years on average.

Keep ReadingShow less
Community pharmacies falling behind on data security toolkit submissions

The last date for submission is 30 June 2025.

Pic credit: iStock

Community pharmacies falling behind on data security toolkit submissions

More than 50 per cent of the community pharmacies in England have failed to complete their Data Security and Protection Toolkit 2025 with the deadline in less than two weeks.

Necessary guidance regarding the toolkit has previously been provided by Community Pharmacy England (CPE) earlier.

Keep ReadingShow less
Digital guide launched to help patients with osteoporosis

In the UK, over three million people have osteoporosis.

Pic credit: iStock

Digital guide launched to help patients with osteoporosis

The Royal Osteoporosis Society (ROS) has launched a free online service called BoneMed which is aimed to support patients with osteoporosis in taking their medicine and remove barriers to adherence.

After completing a five-minute online survey, patients will be emailed a summary of the medicine they have been prescribed and six further updates throughout the year on their medication.

Keep ReadingShow less
GPhC five-year plan to empower pharmacists, uphold public trust

GPhC's Strategic Plan 2025-30 will focus on empowering pharmacists and pharmacy technicians.

iStock

GPhC five-year plan to empower pharmacists, uphold public trust

The General Pharmaceutical Council (GPhC) launched its new plan for the next five years to uphold safety, quality and public trust in pharmacy.

The regulatory body unveiled its Strategic Plan 2025-30 during a Parliamentary event attended by pharmacy minister Stephen Kinnock on Wednesday (18).

Keep ReadingShow less
Glucose monitor and test strips on a blood sugar tracker sheet with lancets and pen device.

Medical device manufacturers will have to monitor the safety and performance of their products already in use.

iStock

Medical device regulation overhauled to improve patients' safety

Medical device manufacturers must now adhere to the UK's post-market surveillance (PMS) regulations.

The new rule came into effect on June 16, and manufacturers will have to monitor the safety and performance of their products already in use.

Keep ReadingShow less